Retatrutide: 24.2% vs 15% — Not Even Close
Last updated: May 2026 · Phase 2 NEJM 2023 results →
Semaglutide (Ozempic/Wegovy) achieved ~15% in STEP-1. Tirzepatide hit ~22% in SURMOUNT-1. Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% body weight loss at 12mg over 48 weeks — the highest of the class. Its Phase 3 TRIUMPH program is still ongoing. Here's what makes the triple agonist different and what the data actually shows.
(Retatrutide Phase 2, 12mg/48wk)
Semaglutide
(vs 1 for Ozempic)
📋 On this page
Head-to-Head: Average Weight Loss
All three drugs compared. Percentages represent average body weight reduction across clinical trial populations. Cross-trial comparisons have limitations — different patient populations and trial designs.
Cross-trial caveat: These drugs were tested in separate clinical trials with different patient populations. Direct head-to-head comparison does not exist yet. The data reflects each drug's average reported weight loss in its respective trials. Individual results vary significantly based on starting weight, diet, exercise, and adherence.
The Triple Receptor Advantage
Semaglutide hits one target. Tirzepatide hits two. Retatrutide hits three — and that third target (glucagon) is what separates it from the pack.
GLP-1 + GIP + Glucagon receptor activation simultaneously. Semaglutide activates only GLP-1 (appetite/satiety). Tirzepatide adds GIP (insulin sensitivity, fat storage). Retatrutide adds glucagon — which actively increases energy expenditure and fat oxidation. This is the critical third leg.
Glucagon receptor activation increases basal metabolic rate and promotes direct fat oxidation (lipolysis). Most GLP-1 drugs work primarily by reducing food intake. Retatrutide adds a metabolic component — you're burning more fat even at rest, not just eating less. This is why the weight loss profile exceeds what appetite suppression alone can achieve.
Retatrutide doesn't just suppress hunger — it reduces habitual eating patterns. The "food noise" that drives late-night snacking, portion oversizing, or the chocolate-after-dinner reflex is significantly blunted. Users report not being prevented from eating, but simply not being pulled toward excess. This is a qualitatively different experience than willpower-based dieting.
Clinical reports note clearing of acanthosis nigricans (insulin resistance skin marker) before significant weight loss occurs. Metabolic benefits — improved insulin sensitivity, reduced liver fat — appear to precede and go beyond what weight loss alone would explain. The drug appears to repair underlying metabolic dysfunction, not just address its symptom.
What It Actually Costs
Retail pricing makes GLP-1 drugs inaccessible for most people without insurance. The pricing landscape across channels varies dramatically.
⚠️ Research peptide vendors: Not FDA-regulated, not intended for human therapeutic use, quality varies significantly by vendor. Compounding pharmacies are regulated and require a prescription. Retail brand drugs are FDA-approved and physician-supervised. Know the difference and the risks of each option.
Phase 3 Timeline
Where retatrutide stands in its path to FDA approval as of May 2026 — following the TRIUMPH-1 obesity readout. Full Phase 3 breakdown →
🦴 Semaglutide's Cartilage Finding: Does Retatrutide Do The Same?
A landmark 2026 study published in Cell Metabolism (Qin et al.) revealed that semaglutide increases articular cartilage thickness by 17% over 24 weeks — through a mechanism entirely independent of weight loss. GLP-1 receptors expressed on chondrocytes (cartilage cells) activate an AMPK-PFKFB3 metabolic pathway that directly stimulates cartilage repair.
This is a paradigm shift: semaglutide isn't just reducing joint load through weight loss — it's directly regenerating cartilage tissue at the cellular level. Participants who underwent cartilage transplants while on semaglutide showed markedly improved graft survival compared to controls.
Citation: Qin et al. (2026). "GLP-1 receptor activation drives chondrocyte metabolic reprogramming." Cell Metabolism. DOI: 10.1016/j.cmet.2026.01.008
Whether retatrutide — a triple agonist (GLP-1/GIP/glucagon) — produces similar cartilage regeneration is not yet established in published literature. GLP-1 receptor activation appears to be the key driver; retatrutide does target GLP-1R, so the mechanism could theoretically apply, but direct cartilage studies for retatrutide have not been published as of early 2026.
→ Full Research Breakdown: Semaglutide and Cartilage Regeneration
Mental Clarity, Cognition & Inflammation
Beyond fat loss, retatrutide users frequently report sharper focus and less inflammatory "stiffness." Here is the receptor-level mechanism — and exactly where the evidence stops.
Cognition. GLP-1 receptors are expressed in the hippocampus and prefrontal cortex — the regions behind memory and executive focus. In randomized trials, liraglutide slowed cognitive decline in mild-to-moderate Alzheimer's disease (Edison et al. 2026, PMID 41326666) and exenatide preserved off-medication motor function in Parkinson's (Athauda et al. 2017, PMID 28781108). Retatrutide adds GIP and glucagon receptor activity — both neurotrophic in preclinical models — so the sharper focus and reduced "brain fog" users describe has a plausible receptor basis.
Inflammation. GLP-1 / GIP dual agonism reduced neuroinflammation and protected synaptic numbers and synaptic activity across multiple preclinical Alzheimer's and Parkinson's models (Hölscher review, PMID 29402504). Systemically, much of the anti-inflammatory benefit is downstream of fat loss itself: visceral adipose tissue is a primary source of IL-6 and TNF-α, and retatrutide drives some of the largest fat-mass reductions in the GLP-1 class — 24.2% mean body weight loss at 48 weeks (12 mg) in the Phase 2 obesity trial (Jastreboff et al. 2023, PMID 37366315). Less adipose mass means less inflammatory signaling.
Key Takeaways
- 24.2% body weight loss at 48 weeks (12mg) in the Phase 2 trial (NEJM 2023) vs ~15% for semaglutide (STEP-1) and ~22% for tirzepatide (SURMOUNT-1) — the largest effect reported in the GLP-1 class; Phase 3 TRIUMPH topline still pending
- Triple receptor mechanism (GLP-1 + GIP + Glucagon) explains enhanced efficacy
- Glucagon activation adds metabolic/fat-burning component absent from semaglutide
- Phase 2 data published and publicly available
- Eli Lilly is actively running Phase 3 TRIUMPH trials
- Well-tolerated in Phase 2 with GI side effects similar to other GLP-1 class drugs
- Full Phase 3 long-term safety data not yet published
- Cardiovascular outcome data still pending
- Not yet FDA approved — NDA expected following the May 2026 Phase 3 TRIUMPH readout
- Long-term weight maintenance after discontinuation not fully characterized
- Research peptide quality is unregulated — purity and identity not guaranteed
- No head-to-head RCT directly comparing retatrutide vs tirzepatide
🛒 Recommended Supplies
Research supplies relevant to injectable GLP-1 class peptides.
Affiliate links help support HighPeptides at no extra cost to you.
Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is NOT currently FDA-approved for human use. It is an investigational compound in Phase 3 clinical trials as of March 2026. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved but require a prescription. Weight loss percentages cited reflect clinical trial averages — individual results vary. Research peptide vendors are not FDA-regulated; purity and identity are not guaranteed. Always consult a qualified healthcare provider before use. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.